Kano Hideyuki, Lunsford L Dade
Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA,
Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Prog Neurol Surg. 2019;34:200-206. doi: 10.1159/000493065. Epub 2019 May 16.
Stereotactic radiosurgery (SRS) has become a standard management option for less common glial tumors. When imaging defines a recurrent or progressive ependymoma after initial resection in a child who has completed adjuvant fractionated radiation therapy, SRS may be used as a boost or salvage strategy. For patients with oligodendrogliomas diagnosed by biopsy or after cytoreductive surgery, SRS may be used as a primary option in smaller volume tumors, or as an adjuvant option for tumors that have progressed after initial surgery, chemotherapy, or fractionated radiation therapy. Currently the increasing use of molecular markers in both tumors helps to define the prognosis, risk of recurrence, and perhaps response to boost or salvage SRS. This report examines the role of SRS in these less common glial tumors.
立体定向放射外科(SRS)已成为治疗较罕见胶质肿瘤的标准管理选择。当影像学显示在完成辅助性分次放疗的儿童初次切除术后出现复发性或进展性室管膜瘤时,SRS可作为强化或挽救策略使用。对于经活检或减瘤手术后诊断为少突胶质细胞瘤的患者,SRS可用于较小体积肿瘤的主要治疗选择,或作为初次手术、化疗或分次放疗后进展肿瘤的辅助治疗选择。目前,这两种肿瘤中分子标志物的使用日益增多,有助于确定预后、复发风险,或许还有对强化或挽救性SRS的反应。本报告探讨了SRS在这些较罕见胶质肿瘤中的作用。